Emerging Immune-Oncology Targets

While cancer therapy has created a large leap within the past 5 years, the bulk of therapies at advanced stages of development square measure clustered in a very similar target house. The enlarged investment in immuno-oncology has created associate degree imperative chance to find and populate new target areas that either gift new categories of immunotherapies or is utilized in Combination with existing  products.

  • Emerging immunomodulatory targets
  • Checkpoint inhibitors (PD-1/PD-L1, CTLA-4, TIM3, LAG3)
  • Targeting agonist receptors (OX40, 4-1BB, GITR, CD27, ICOS, GITR)
  • Targeting agonist receptors (OX40, 4-1BB, GITR, CD27, ICOS, GITR)
  • Targeting tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs)
  • Targeting the STING pathway
  • Targeting CD96 and TIGIT for cancer immunotherapy
  • Targeting the stroma, tumor micro environment
  • Targeting innate immunity
  • Rational combination Immuno therapy

Related Conference of Emerging Immune-Oncology Targets

Emerging Immune-Oncology Targets Conference Speakers